vs
Niagen Bioscience, Inc.（NAGE）与RxSight, Inc.（RXST）财务数据对比。点击上方公司名可切换其他公司
Niagen Bioscience, Inc.的季度营收约是RxSight, Inc.的1.0倍（$33.8M vs $32.6M），Niagen Bioscience, Inc.净利率更高（12.2% vs -28.1%，领先40.3%），Niagen Bioscience, Inc.同比增速更快（16.2% vs -18.9%），过去两年Niagen Bioscience, Inc.的营收复合增速更高（23.6% vs 5.1%）
Niagen Bioscience（原名为ChromaDex）是一家成立于1999年，总部位于加利福尼亚州洛杉矶的生物科技公司。公司业务涵盖标准品、膳食补充剂以及原料技术开发多个领域，目前在纳斯达克挂牌上市。
RxSight是一家医疗科技企业，专注于研发和商业化适用于白内障及屈光晶状体置换手术的可调光人工晶状体产品，其核心产品支持术后通过专用照光设备调整晶状体度数，为全球眼科诊疗市场提供优化的术后视力解决方案。
NAGE vs RXST — 直观对比
营收规模更大
NAGE
是对方的1.0倍
$32.6M
营收增速更快
NAGE
高出35.1%
-18.9%
净利率更高
NAGE
高出40.3%
-28.1%
两年增速更快
NAGE
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.8M | $32.6M |
| 净利润 | $4.1M | $-9.2M |
| 毛利率 | 64.1% | 77.5% |
| 营业利润率 | 12.1% | -34.8% |
| 净利率 | 12.2% | -28.1% |
| 营收同比 | 16.2% | -18.9% |
| 净利润同比 | -42.4% | -54.1% |
| 每股收益（稀释后） | $0.05 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NAGERXST
| Q4 25 | $33.8M | $32.6M | ||
| Q3 25 | $34.0M | $30.3M | ||
| Q2 25 | $31.1M | $33.6M | ||
| Q1 25 | $30.5M | $37.9M | ||
| Q4 24 | $29.1M | $40.2M | ||
| Q3 24 | $25.6M | $35.3M | ||
| Q2 24 | $22.7M | $34.9M | ||
| Q1 24 | $22.2M | $29.5M |
净利润NAGERXST
| Q4 25 | $4.1M | $-9.2M | ||
| Q3 25 | $4.6M | $-9.8M | ||
| Q2 25 | $3.6M | $-11.8M | ||
| Q1 25 | $5.1M | $-8.2M | ||
| Q4 24 | $7.2M | $-5.9M | ||
| Q3 24 | $1.9M | $-6.3M | ||
| Q2 24 | $-15.0K | $-6.1M | ||
| Q1 24 | $-492.0K | $-9.1M |
毛利率NAGERXST
| Q4 25 | 64.1% | 77.5% | ||
| Q3 25 | 64.5% | 79.9% | ||
| Q2 25 | 65.0% | 74.9% | ||
| Q1 25 | 63.4% | 74.8% | ||
| Q4 24 | 62.5% | 71.6% | ||
| Q3 24 | 63.5% | 71.4% | ||
| Q2 24 | 60.2% | 69.5% | ||
| Q1 24 | 60.7% | 70.1% |
营业利润率NAGERXST
| Q4 25 | 12.1% | -34.8% | ||
| Q3 25 | 12.5% | -40.1% | ||
| Q2 25 | 10.2% | -41.6% | ||
| Q1 25 | 15.7% | -28.2% | ||
| Q4 24 | 24.4% | -21.5% | ||
| Q3 24 | 6.3% | -26.1% | ||
| Q2 24 | -1.1% | -23.9% | ||
| Q1 24 | -3.3% | -36.2% |
净利率NAGERXST
| Q4 25 | 12.2% | -28.1% | ||
| Q3 25 | 13.5% | -32.4% | ||
| Q2 25 | 11.6% | -35.0% | ||
| Q1 25 | 16.6% | -21.6% | ||
| Q4 24 | 24.6% | -14.8% | ||
| Q3 24 | 7.3% | -17.9% | ||
| Q2 24 | -0.1% | -17.4% | ||
| Q1 24 | -2.2% | -30.8% |
每股收益（稀释后）NAGERXST
| Q4 25 | $0.05 | $-0.22 | ||
| Q3 25 | $0.05 | $-0.24 | ||
| Q2 25 | $0.04 | $-0.29 | ||
| Q1 25 | $0.06 | $-0.20 | ||
| Q4 24 | $0.10 | $-0.14 | ||
| Q3 24 | $0.02 | $-0.16 | ||
| Q2 24 | $0.00 | $-0.16 | ||
| Q1 24 | $-0.01 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $228.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $76.5M | $275.7M |
| 总资产 | $106.4M | $311.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NAGERXST
| Q4 25 | — | $228.1M | ||
| Q3 25 | $64.1M | $227.5M | ||
| Q2 25 | $60.3M | $227.5M | ||
| Q1 25 | $55.5M | $229.3M | ||
| Q4 24 | $44.5M | $237.2M | ||
| Q3 24 | $32.2M | $237.1M | ||
| Q2 24 | $27.7M | $233.3M | ||
| Q1 24 | $27.4M | $125.4M |
股东权益NAGERXST
| Q4 25 | $76.5M | $275.7M | ||
| Q3 25 | $70.7M | $276.0M | ||
| Q2 25 | $64.2M | $278.0M | ||
| Q1 25 | $55.3M | $279.3M | ||
| Q4 24 | $46.1M | $281.2M | ||
| Q3 24 | $34.4M | $277.3M | ||
| Q2 24 | $30.7M | $275.2M | ||
| Q1 24 | $29.0M | $163.9M |
总资产NAGERXST
| Q4 25 | $106.4M | $311.8M | ||
| Q3 25 | $98.1M | $308.5M | ||
| Q2 25 | $91.5M | $309.0M | ||
| Q1 25 | $81.3M | $313.0M | ||
| Q4 24 | $68.3M | $318.6M | ||
| Q3 24 | $56.5M | $310.5M | ||
| Q2 24 | $54.0M | $305.5M | ||
| Q1 24 | $54.1M | $183.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $679.0K | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-2.3M |
| 自由现金流率自由现金流/营收 | — | -6.9% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 0.16× | — |
| 过去12个月自由现金流最近4个季度 | — | $-19.3M |
8季度趋势，按日历期对齐
经营现金流NAGERXST
| Q4 25 | $679.0K | $-1.1M | ||
| Q3 25 | $3.7M | $-1.2M | ||
| Q2 25 | $1.3M | $-4.4M | ||
| Q1 25 | $7.9M | $-8.8M | ||
| Q4 24 | $8.6M | $-4.3M | ||
| Q3 24 | $3.5M | $650.0K | ||
| Q2 24 | $-264.0K | $-4.0M | ||
| Q1 24 | $295.0K | $-9.3M |
自由现金流NAGERXST
| Q4 25 | — | $-2.3M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | $-5.9M | ||
| Q1 25 | — | $-9.4M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $-453.0K | ||
| Q2 24 | — | $-5.5M | ||
| Q1 24 | — | $-11.3M |
自由现金流率NAGERXST
| Q4 25 | — | -6.9% | ||
| Q3 25 | — | -5.8% | ||
| Q2 25 | — | -17.6% | ||
| Q1 25 | — | -24.8% | ||
| Q4 24 | — | -12.7% | ||
| Q3 24 | — | -1.3% | ||
| Q2 24 | — | -15.9% | ||
| Q1 24 | — | -38.2% |
资本支出强度NAGERXST
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | 6.7% |
现金转化率NAGERXST
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.81× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 1.56× | — | ||
| Q4 24 | 1.20× | — | ||
| Q3 24 | 1.86× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NAGE
| TRUNIAGEN Consumer Product | $27.5M | 81% |
| Ingredients Segment | $5.7M | 17% |
| Other | $694.0K | 2% |
RXST
| Rxlal | $28.2M | 86% |
| LDD | $3.0M | 9% |
| Service Warranty Service Contracts And Accessories | $1.5M | 4% |
